Compare Lithium Americas Corp (LAC) vs Medtronic PLC (MDT) Price & Performance

Lithium Americas (LAC) trades at $2.90, down 1.69% amid bearish technical signals despite recent earnings beats. The company shows negative profitability with ROE at -11.35% and net income of -$122.09M for 2025, though it maintains strong financing cash flow of $1.14B. Construction milestones at Thacker Pass project progress, with 2026 expected to be pivotal for operational developments according to company guidance.

Investment outlook balances significant project potential against substantial execution risks. While analyst consensus leans positive with 47% buy ratings and no sell recommendations, the stock faces headwinds from negative cash flow from operations and high capital expenditure requirements. Key risks include dilution from share issuances and sensitivity to lithium market dynamics.

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.